

Commercial/Healthcare Exchange PA Criteria Effective: December 20th, 2019

Prior Authorization: Gloperba

Products Affected: Gloperba (colchicine) oral solution

Medication Description: Colchicine's effectiveness as a prophylactic treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β -tubulin into microtubules, thereby preventing the activation, degranulation and migration of neutrophils to sites of inflammation. Colchicine also interferes with the inflammasome complex found in neutrophils and monocytes that mediates interleukin-1 β (IL-1 β) activation.

Covered Uses: Prophylaxis of gout flares in adults.

Exclusion Criteria:

1. Patients with renal **or** hepatic impairment should not be given GLOPERBA in conjunction with drugs that inhibit both CYP3A4 and P-gp.
2. Patients with both renal **and** hepatic impairment should not be given GLOPERBA.
3. Acute treatment of gout flares during prophylaxis
4. Treatment of pain from other causes other than gout

Required Medical Information:

1. Diagnosis
2. Previous therapies tried/failed
3. Medical history

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

- A. Patient is using this medication for a diagnosis of gout prophylaxis; **AND**
- B. The patient is unable to ingest oral Colcris tablets **AND** Mitigare capsules due to one of the following:
 - i. Oral/motor difficulties; **OR**
 - ii. Dysphagia

References:

1. Product Information: GLOPERBA(R) oral solution, colchicine oral solution. Romeg Therapeutics LLC (per FDA), Woburn, MA, 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	12/5/19
2	Update	Other Criteria	Other Criteria – added Mitigare	03/27/2020

